Publikationen in Zusammenarbeit mit Forschern von Academic Medical Center (9)

2023

  1. Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial

    JHEP Reports, Vol. 5, Núm. 5

  2. Prognostic role of radiomics-based body composition analysis for the 1-year survival for hepatocellular carcinoma patients

    Journal of Cachexia, Sarcopenia and Muscle, Vol. 14, Núm. 5, pp. 2301-2309

2022

  1. Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 49, Núm. 13, pp. 4716-4726

  2. Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial

    Journal of Cancer Research and Clinical Oncology, Vol. 148, Núm. 2, pp. 475-485

  3. Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial

    Journal of Cancer Research and Clinical Oncology, Vol. 148, Núm. 9, pp. 2487-2496

  4. The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality

    The Lancet, Vol. 399, Núm. 10319, pp. 61-116

2021

  1. Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization

    EJNMMI Research, Vol. 11, Núm. 1

2020

  1. Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach

    Hepatology, Vol. 72, Núm. 1, pp. 198-212

2015

  1. Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: Analysis of the European multicentre trial SORAMIC

    Liver International, Vol. 35, Núm. 2, pp. 620-626